<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04533503</url>
  </required_header>
  <id_info>
    <org_study_id>003175</org_study_id>
    <nct_id>NCT04533503</nct_id>
  </id_info>
  <brief_title>Vis-Rx Post-Market Evaluation</brief_title>
  <acronym>Vis-Rx PME</acronym>
  <official_title>Post-Market Clinical Evaluation of the Gentuity High-Frequency Optical Coherence Tomography Imaging System and Vis-Rx Micro-Imaging Catheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gentuity, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gentuity, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-market clinical evaluation of the Gentuity High-Frequency Optical Coherence Tomography&#xD;
      (HF-OCT) System and the Vis-Rx Micro-Imaging Catheter for use in Percutaneous Coronary&#xD;
      Intervention (PCI) procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, single-arm, unblinded, multi-center, post-market clinical evaluation assessing&#xD;
      the imaging capabilities of the Gentuity HF-OCT System and the Vis-Rx Micro-Imaging Catheter&#xD;
      for use in PCI procedures. Objectives are to evaluate the clinical and technical performance&#xD;
      in the target patient population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical performance</measure>
    <time_frame>Immediately after the procedure</time_frame>
    <description>Operator evaluation of performance via Likert scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Technical performance</measure>
    <time_frame>Up to 3 months following the procedure</time_frame>
    <description>Objective measurement of image clarity of the HF-OCT images by an independent core lab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete pullbacks</measure>
    <time_frame>Up to 3 months following the procedure</time_frame>
    <description>Percentage of HF-OCT images with maximum clear image length</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>HF-OCT imaging</arm_group_label>
    <description>Enrolled subjects who meet lesion-specific eligibility criteria and undergo HF-OCT imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HF-OCT Imaging with the Vis-Rx Micro-Imaging Catheter</intervention_name>
    <description>Intracoronary HF-OCT imaging of the target lesion(s) during the procedure.</description>
    <arm_group_label>HF-OCT imaging</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in the cardiac catheterization lab who are candidates for transluminal&#xD;
        interventional procedures&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Willing and able to provide written informed consent to participate&#xD;
&#xD;
          -  Transluminal interventional procedure for their coronary arteries&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          -  Bacteremia or sepsis&#xD;
&#xD;
          -  Major coagulation system abnormalities&#xD;
&#xD;
          -  Severe hemodynamic instability or shock&#xD;
&#xD;
          -  Acute renal failure&#xD;
&#xD;
          -  Disqualified for Coronary Artery Bypass Graft (CABG) surgery&#xD;
&#xD;
          -  Disqualified for PCI procedure&#xD;
&#xD;
          -  Currently enrolled in another study to evaluate an investigational device or&#xD;
             medication&#xD;
&#xD;
        Lesion-Specific Exclusion Criteria:&#xD;
&#xD;
          -  Total occlusion&#xD;
&#xD;
          -  Coronary artery spasm&#xD;
&#xD;
          -  Large thrombus (visible under angiography)&#xD;
&#xD;
          -  Any target vessel which has undergone a bypass procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nick Ventura</last_name>
    <phone>9787673473</phone>
    <email>nventura@gentuity.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fadi A Matar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Tyler Richmond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aaron Kaplan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>August 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

